Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Huanting Chi *Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0002-2347-8782
Bingqian Qu *Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0002-7330-2929
Angga PrawiraMolecular Virology, Department of Infectious Diseases, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Talisa RichardtMolecular Virology, Department of Infectious Diseases, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Lars MaurerSchaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Jungen HuSchaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Rebecca M FuSchaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Florian A LemppMolecular Virology, Department of Infectious Diseases, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.ORCID 0000-0001-6103-8078
Zhenfeng ZhangMolecular Virology, Department of Infectious Diseases, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Dirk GrimmGerman Centre for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany.ORCID 0000-0001-6227-5665
Xianfang WuInfection Biology Program and Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-2995-935X
Stephan Urban *German Centre for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany. Stephan.Urban@med.uni-heidelberg.de.ORCID 0000-0003-1560-8038
Viet Loan Dao Thi *Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany. VietLoan.DaoThi@med.uni-heidelberg.de.ORCID 0000-0003-2293-3592
Funding
Developing a renewable and dissectible human liver for the study of HBV/HCV infectionDP2AI170515 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Xianfang Wu · 2022 to 2026
$2.4M
Bundesministerium für Bildung und Forschung (BMBF) VIRASCREEN 01KI211Deutsche Forschungsgemeinschaft (DFG) 240245660-SFB1129Deutsche Forschungsgemeinschaft (DFG) 272983813-SFB/TRR 179Deutsches Zentrum für Infektionsforschung (DZIF) 05.704Deutsches Zentrum für Infektionsforschung (DZIF) 05.806Deutsches Zentrum für Infektionsforschung (DZIF) 05.823Foundation for the National Institutes of Health (FNIH) DP2-AI170515Heidelberg University SFB/TRR179NIAID NIH HHS DP2 AI170515
6 · The paper itself
Abstract
Current culture systems available for studying hepatitis D virus (HDV) are suboptimal. In this study, we demonstrate that hepatocyte-like cells (HLCs) derived from human pluripotent stem cells (hPSCs) are fully permissive to HDV infection across various tested genotypes. When co-infected with the helper hepatitis B virus (HBV) or transduced to express the HBV envelope protein HBsAg, HLCs effectively release infectious progeny virions. We also show that HBsAg-expressing HLCs support the extracellular spread of HDV, thus providing a valuable platform for testing available anti-HDV regimens. By challenging the cells along the differentiation with HDV infection, we have identified CD63 as a potential HDV co-entry factor that was rate-limiting for HDV infection in immature hepatocytes. Given their renewable source and the potential to derive hPSCs from individual patients, we propose HLCs as a promising model for investigating HDV biology. Our findings offer new insights into HDV infection and expand the repertoire of research tools available for the development of therapeutic interventions.
Indexed as
Cell DifferentiationHepatitis BHepatitis B virusHepatitis Delta VirusHepatocytesPluripotent Stem CellsHepatitis B Surface AntigensHepatitis DHumansVirus InternalizationVirus ReplicationHepatitis B Surface AntigensAntiviral TreatmentHepatitis B VirusHepatitis D VirusHepatocyte-like CellsHuman Pluripotent Stem Cells
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
An hepatitis B and D virus infection model using human pluripotent stem cell-derived hepatocytes. · full record | Socratic